Abstract
Mannose receptors (MR) are highly over-expressed on macrophages in the inflammatory bowel disease (IBD) and can be targeted by developing mannose-anchored nano-carrier system. In this study, mannosylated chitosan (MC) polymer was synthesized because of its high affinity for mannose receptors. Afterward, MC nanoparticles (NPs) were fabricated encapsulating dexamethasone to target macrophages for attenuation of inflammation at initial stages. Further, NPs were coated with a pH-sensitive polymer to control the premature drug release in the stomach. NPs were optimized using a surface response quadratic model to study the impact of various process parameters. Optimized NPs were then characterized for size, morphology, zeta potential, surface chemistry, biocompatibility, and uptake by macrophages. The average particle size was found to be 380 ± 19.8 nm with an encapsulation efficiency of 78.1 ± 1.17%. pH-dependent drug release profile was obtained with an average release of 73.9 ± 5.24% over 72 h in simulated intestinal fluid (pH 7.4). Moreover, the NPs uptake by the macrophages supported the viability of macrophages with the NPs and did not show any adverse effects. Moreover, this study was supported by the uptake of NPs inside macrophages. Altogether, the data supported that MC NPs could serve as a potential anti-inflammatory therapeutic approach to target macrophages in IBD.
Similar content being viewed by others
Abbreviations
- CD:
-
Crohn’s disease
- DEXA:
-
Dexamethasone
- DSC:
-
Differential scanning calorimetry
- EE:
-
Encapsulation efficiency
- ES100:
-
Poly (methacrylic acid-co-methyl methacrylate) 1:2, Eudragit® S100
- FBS:
-
Fetal bovine serum
- FTIR:
-
Fourier transform infrared spectroscopy
- GIT:
-
Gastrointestinal tract
- IBD:
-
Inflammatory bowel disease
- IRFs:
-
Interferons
- MC:
-
Mannosylated chitosan
- MR:
-
Mannose receptor
- NF-κB:
-
Nuclear factor-kappa activated B cells
- NPs:
-
Nanoparticles
- PAF:
-
Platelet activating factor
- PAMPs:
-
Pathogen-associated molecular patterns
- PDI:
-
Polydispersity index
- PRRs:
-
Pattern recognition receptors
- Rh-B:
-
Rhomadine B
- SEM:
-
Scanning electron microscope
- SGF:
-
Simulated gastric fluid
- SIF:
-
Simulated intestinal fluid
- TC:
-
Thiolated chitosan
- TGA:
-
Thioglycolic acid
- UC:
-
Ulcerative colitis
- XPS:
-
X-ray photon spectroscopy
References
Afzal I, Sarwar HS, Sohail MF, Varikuti S, Jahan S, Akhtar S, Yasinzai M, Satoskar AR, Shahnaz G (2019) Mannosylated thiolated paromomycin-loaded PLGA nanoparticles for the oral therapy of visceral leishmaniasis. Nanomedicine 14:387–406
Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124:783–801
Ali H, Weigmann B, Neurath M, Collnot E, Windbergs M, Lehr C-M (2014) Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases. J Control Release 183:167–177
Ali H, Weigmann B, Collnot E-M, Khan SA, Windbergs M, Lehr C-M (2016) Budesonide loaded PLGA nanoparticles for targeting the inflamed intestinal mucosa—pharmaceutical characterization and fluorescence imaging. Pharm Res 33:1085–1092
Baer DR, Engelhard MH (2010) XPS analysis of nanostructured materials and biological surfaces. J Electron Spectrosc Relat Phenom 178:415–432
Beaugerie L, Langholz E, Nyboe-Andersen N, Pigneur B, Sokol H, Epicom E (2018) Differences in epidemiological features between ulcerative colitis and Crohn’s disease: the early life-programmed versus late dysbiosis hypothesis. Med Hypotheses 115:19–21
Bernkop-Schnürch A, Schwarz V, Steininger S (1999) Polymers with thiol groups: a new generation of mucoadhesive polymers? Pharm Res 16:876–881
Bruschi ML (2015) Mathematical models of drug release. Strategies to modify the drug release from pharmaceutical systems. Woodhead Publishing, Cambridge, p 63
Chakraborty P, Ghosh D, Basu MK (2001) Modulation of macrophage mannose receptor affects the uptake of virulent and avirulent Leishmania donovani promastigotes. J Parasitol 87:1023–1027
Chaubey P, Mishra B (2014) Mannose-conjugated chitosan nanoparticles loaded with rifampicin for the treatment of visceral leishmaniasis. Carbohyd Polym 101:1101–1108
Chaubey P, Patel RR, Mishra B (2014) Development and optimization of curcumin-loaded mannosylated chitosan nanoparticles using response surface methodology in the treatment of visceral leishmaniasis. Expert Opin Drug Deliv 11:1163–1181
Chawla A, Sharma P, Pawar P (2012) Eudragit S-100 coated sodium alginate microspheres of naproxen sodium: formulation, optimization and in vitro evaluation. Acta Pharm 62:529–545
Davies M, Wilding I, Short R, Khan M, Watts J, Melia C (1989) An analysis of the surface chemical structure of polymethacrylate (Eudragit) film coating polymers by XPS. Int J Pharm 57:183–187
Dehshahri A, Oskuee RK, Ramezani M (2012) Plasmid DNA delivery into hepatocytes using a multifunctional nanocarrier based on sugar-conjugated polyethylenimine. Gene Ther Mol Biol 14:62–71
Fu Y, Kao WJ (2010) Drug release kinetics and transport mechanisms of non-degradable and degradable polymeric delivery systems. Expert Opin Drug Deliv 7:429–444
Giron F, Pastó A, Tasciotti E, Abraham BP (2019) Nanotechnology in the treatment of inflammatory bowel disease. Inflamm Bowel Dis 25(12):1871–1880
Hatami E, Mu Y, Shields DN, Chauhan SC, Kumar S, Cory TJ, Yallapu MM (2019) Mannose-decorated hybrid nanoparticles for enhanced macrophage targeting. Biochem Biophys Rep 17:197–207
Hoshyar N, Gray S, Han H, Bao G (2016) The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine 11:673–692
Hu D, Liu L, Chen W, Li S, Zhao Y (2012) A novel preparation method for 5-aminosalicylic acid loaded Eudragit S100 nanoparticles. Int J Mol Sci 13:6454–6468
ICH, I. G. Q3c (R6) (2016) on Impurities: guideline for residual solvents. International conference for harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH), Switzerland, 2016
Katta R, Deveswaran R, Bharath S, Basavaraj B (2017) Development of mesalazine microspheres for colon targeting. J Pharm Res 9:1–9
Mazzarino L, Travelet C, Ortega-Murillo S, Otsuka I, Pignot-Paintrand I, Lemos-Senna E, Borsali R (2012) Elaboration of chitosan-coated nanoparticles loaded with curcumin for mucoadhesive applications. J Colloid Interface Sci 370:58–66
Mukhtar M, Ali H, Ahmed N, Munir R, Talib S, Khan AS, Ambrus R (2020) Drug delivery to macrophages: A review of nano-therapeutics targeted approach for inflammatory disorders and cancer. Expert Opin Drug Deliv. https://doi.org/10.1080/17425247.2020.1783237
Niu X, Zhang H, Li W, Mu Q, Yao H, Wang Y (2015) Anti-inflammatory effects of cavidine in vitro and in vivo, a selective COX-2 inhibitor in LPS-induced peritoneal macrophages of mouse. Inflammation 38:923–933
Pertuit D, Moulari B, Betz T, Nadaradjane A, Neumann D, Ismaïli L, Refouvelet B, Pellequer Y, Lamprecht A (2007) 5-Amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease. J Control Release 123:211–218
Sartor RB (2006) Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Rev Gastroenterol Hepatol 3:390
Shahnaz G, Edagwa BJ, McMillan J, Akhtar S, Raza A, Qureshi NA, Yasinzai M, Gendelman HE (2017) Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis. Nanomedicine (Lond) 12:99–115
Sriamornsak P, Thirawong N, Weerapol Y, Nunthanid J, Sungthongjeen S (2007) Swelling and erosion of pectin matrix tablets and their impact on drug release behavior. Eur J Pharm Biopharm 67:211–219
Tams Todd RT (2003) Diseases of the stomach. In: Handbook of small animal gastroenterology. W B Saunders Company, pp 159–194
Thakral NK, Ray AR, Majumdar DK (2010) Eudragit S-100 entrapped chitosan microspheres of valdecoxib for colon cancer. J Mater Sci Mater Med 21:2691–2699
Tukulula M, Hayeshi R, Fonteh P, Meyer D, Ndamase A, Madziva MT, Khumalo V, Lubuschagne P, Naicker B, Swai H (2015) Curdlan-conjugated PLGA nanoparticles possess macrophage stimulant activity and drug delivery capabilities. Pharm Res 32:2713–2726
Vafaei SY, Esmaeili M, Amini M, Atyabi F, Ostad SN, Dinarvand R (2016) Self assembled hyaluronic acid nanoparticles as a potential carrier for targeting the inflamed intestinal mucosa. Carbohyd Polym 144:371–381
Weissleder R, Nahrendorf M, Pittet MJ (2014) Imaging macrophages with nanoparticles. Nat Mater 13:125
Xu B, Zhang W, Chen Y, Xu Y, Wang B, Zong L (2018) Eudragit® L100-coated mannosylated chitosan nanoparticles for oral protein vaccine delivery. Int J Biol Macromol 113:534–542
Yang W, Fu J, Wang T, He N (2009) Chitosan/sodium tripolyphosphate nanoparticles: Preparation, characterization and application as drug carrier. J Biomed Nanotechnol 5:591–595
Zeeshan M, Ali H, Khan S, Khan SA, Weigmann B (2019a) Advances in orally-delivered pH-sensitive nanocarrier systems; an optimistic approach for the treatment of inflammatory bowel disease. Int J Pharm 558:201–214
Zeeshan M, Ali H, Khan S, Mukhtar M, Khan MI, Arshad M (2019b) Glycyrrhizic acid-loaded pH-sensitive poly-(lactic-co-glycolic acid) nanoparticles for the amelioration of inflammatory bowel disease. Nanomedicine 14:1945–1969
Zhang DL, Deng YF, Li CB, Chen J (2008) Separation of ethyl acetate− ethanol azeotropic mixture using hydrophilic ionic liquids. Ind Eng Chem Res 47:1995–2001
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Mukhtar, M., Zesshan, M., Khan, S. et al. Fabrication and optimization of pH-sensitive mannose-anchored nano-vehicle as a promising approach for macrophage uptake. Appl Nanosci 10, 4013–4027 (2020). https://doi.org/10.1007/s13204-020-01510-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13204-020-01510-y